Table 1.
Demographic and clinical characteristic of Ankylosing Spondylitis (AS) patients at switching.
| Parameters | Switched Group (BI) n:45 |
Continued Group (RI) n:43 |
p-Value |
|---|---|---|---|
| Mean age (years) (SD) | 36.1 (4.6) | 35.7 (4.3) | NS |
| Male/female | 39/6 | 40 (3) | NS |
| Mean disease duration (years) (SD) | 7.8 (3.0) | 7.6 (2.8) | NS |
| Mean follow-up (years) (SD) | 7.0 (1.1) | 6.9 (0.9) | NS |
| BMI (kgr/m2) >25 | 5 (11.1) | 4 (9.3) | NS |
| Current smokers n (%) | 10 (22.2) | 8 (18.6) | NS |
| Ex-smokers n (%) | 9 (20) | 9 (20.9) | NS |
| Mean treatment with BI/RI | 6.4 (0.9) | 6.5 (0.8) | NS |
| Mean treatment with RI and clinical remission (years) (SD) | 3.6 (0.8) | NS | |
| Axial disease n (%) | 45 (100) | 43 (100) | NS |
| Peripheral disease n (%) | 4 (9) | 3 (7) | NS |
| Methotrexate intake n (%) | 3 (7) | 2 (5) | NS |
| Mean BASDAI (SD) | 3.7 (0.2) | 3.6 (0.4) | NS |
| Mean ASDAS (SD) | 1.0 (0.2) | 1.1 (0.2) | NS |
| Mean ESR mm/h (SD) | 18.5 (2.2) | 19.3 (1.7) | NS |
| Mean CRP mg/L (SD) | 6.0 (0.8) | 5.8 (0.6) | NS |
BI, biosimilar infliximab; RI, reference infliximab; SD, standard deviation; BMI, body mass index; BASDAI, bath ankylosing spondylitis activity index; ASDAS, ankylosing spondylitis disease activity score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NS, non-statistical.